Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.36 |
| ▸ | PDE4A | P27815 | 4/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900199 | 1.00 | CHRM3 (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29732827 | 0.82 | CHRM3 (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19900207 | 0.82 | CHRM3 (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19899806 | 0.76 | LRRK2 (0.36) | FFAR4 | |
| SCHEMBL19914945 | 0.76 | ACACB (0.33) | NTSR1ACACB | |
| SCHEMBL19900144 | 0.73 | ALDH1A1 (0.36) | FFAR4HRH4PDE10AALDH1A1SCD | |
| SCHEMBL19900284 | 0.71 | ALDH1A1 (0.51) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19914944 | 0.69 | SMN1; SMN2 (0.46) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19900198 | 0.65 | CHRM3 (0.32) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11788368 | 0.65 | PTGS1 (0.34) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390605-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390605-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | DPYD, TYMP, NUDT1 | CHRM3 2248/4885PDE4A 1204/4885PDE4B 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.